Acenocoumarol
Glucagon recombinant may increase the anticoagulant activities of Acenocoumarol.
Aclidinium
The risk or severity of adverse effects can be increased when Aclidinium is combined with Glucagon recombinant.
Atracurium
The risk or severity of adverse effects can be increased when Atracurium is combined with Glucagon recombinant.
Advertisement
Atracurium Besylate
The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Glucagon recombinant.
Atropine
The risk or severity of adverse effects can be increased when Atropine is combined with Glucagon recombinant.
Benactyzine
The risk or severity of adverse effects can be increased when Benactyzine is combined with Glucagon recombinant.
Advertisement
Benztropine
The risk or severity of adverse effects can be increased when Benzatropine is combined with Glucagon recombinant.
Biperiden
The risk or severity of adverse effects can be increased when Biperiden is combined with Glucagon recombinant.
Butylscopolamine
The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Glucagon recombinant.
Advertisement
Chlorphenoxamine
The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Glucagon recombinant.
Cyclopentolate
The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Glucagon recombinant.
Darifenacin
The risk or severity of adverse effects can be increased when Darifenacin is combined with Glucagon recombinant.
Desloratadine
The risk or severity of adverse effects can be increased when Desloratadine is combined with Glucagon recombinant.
Dexetimide
The risk or severity of adverse effects can be increased when Dexetimide is combined with Glucagon recombinant.
Dicumarol
Glucagon recombinant may increase the anticoagulant activities of Dicoumarol.
Dicyclomine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Glucagon recombinant.
Fesoterodine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Glucagon recombinant.
Fluindione
Glucagon recombinant may increase the anticoagulant activities of Fluindione.
Gallamine Triethiodide
The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Glucagon recombinant.
Glycopyrronium
The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Glucagon recombinant.
Homatropine
The risk or severity of adverse effects can be increased when Homatropine is combined with Glucagon recombinant.
Hyoscyamine
The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Glucagon recombinant.
Indomethacin
The therapeutic efficacy of Glucagon recombinant can be decreased when used in combination with Indomethacin.
Ipratropium Bromide
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Glucagon recombinant.
Ipratropium Bromide Anhydrous
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Glucagon recombinant.
Mecamylamine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Glucagon recombinant.
Methantheline
The risk or severity of adverse effects can be increased when Methantheline is combined with Glucagon recombinant.
Methixene
The risk or severity of adverse effects can be increased when Metixene is combined with Glucagon recombinant.
Methscopolamine
The risk or severity of adverse effects can be increased when Methscopolamine is combined with Glucagon recombinant.
Methscopolamine Bromide
The risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Glucagon recombinant.
Octotropine Methylbromide
The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Glucagon recombinant.
Octylonium
The risk or severity of adverse effects can be increased when Otilonium is combined with Glucagon recombinant.
Orphenadrine
The risk or severity of adverse effects can be increased when Orphenadrine is combined with Glucagon recombinant.
Oxitropium
The risk or severity of adverse effects can be increased when Oxitropium is combined with Glucagon recombinant.
Oxybutynin
The risk or severity of adverse effects can be increased when Oxybutynin is combined with Glucagon recombinant.
Oxyphenonium
The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Glucagon recombinant.
Pancuronium
The risk or severity of adverse effects can be increased when Pancuronium is combined with Glucagon recombinant.
Pancuronium Bromide
The risk or severity of adverse effects can be increased when Pancuronium is combined with Glucagon recombinant.
Phenindione
Glucagon recombinant may increase the anticoagulant activities of Phenindione.
Phenprocoumon
Glucagon recombinant may increase the anticoagulant activities of Phenprocoumon.
Pipecuronium
The risk or severity of adverse effects can be increased when Pipecuronium is combined with Glucagon recombinant.
Pirenzepine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Glucagon recombinant.
Procyclidine
The risk or severity of adverse effects can be increased when Procyclidine is combined with Glucagon recombinant.
Profenamine
The risk or severity of adverse effects can be increased when Ethopropazine is combined with Glucagon recombinant.
Propantheline
The risk or severity of adverse effects can be increased when Propantheline is combined with Glucagon recombinant.
Propantheline Bromide
The risk or severity of adverse effects can be increased when Propantheline is combined with Glucagon recombinant.
Propiverine
The risk or severity of adverse effects can be increased when Propiverine is combined with Glucagon recombinant.
Quinidine
The risk or severity of adverse effects can be increased when Quinidine is combined with Glucagon recombinant.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Glucagon recombinant.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Glucagon recombinant.
Solifenacin
The risk or severity of adverse effects can be increased when Solifenacin is combined with Glucagon recombinant.
Tiotropium
The risk or severity of adverse effects can be increased when Tiotropium is combined with Glucagon recombinant.
Tolterodine
The risk or severity of adverse effects can be increased when Tolterodine is combined with Glucagon recombinant.
Trihexyphenidyl
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Glucagon recombinant.
Trihexyphenidyl Hydrochloride
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Glucagon recombinant.
Trimethaphan
The risk or severity of adverse effects can be increased when Trimethaphan is combined with Glucagon recombinant.
Tropicamide
The risk or severity of adverse effects can be increased when Tropicamide is combined with Glucagon recombinant.
Trospium
The risk or severity of adverse effects can be increased when Trospium is combined with Glucagon recombinant.
Tubocurarine
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Glucagon recombinant.
Umeclidinium
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Glucagon recombinant.
Vecuronium
The risk or severity of adverse effects can be increased when Vecuronium is combined with Glucagon recombinant.
Warfarin
Glucagon recombinant may increase the anticoagulant activities of Warfarin.
